Medical Device SBOM: Dynamic Scanning vs Clinical Triage

AdvancedUNO
21 Jul, 2026
Medical Device SBOM: Dynamic Scanning vs Clinical Triage

6 min read

The Reality Behind the Compliance Label

  • The Definition: A medical device SBOM (Software Bill of Materials) is a structured, machine-readable inventory of every software component, open-source library, and dependency embedded within a clinical device.
  • Why It Matters: Under FDA Section 524B of the FD&C Act, manufacturers must provide an SBOM to secure premarket clearance and maintain postmarket safety.
  • The Catch: Vendors sell SBOM tools as push-button compliance, but in production, they generate hundreds of unexploitable vulnerability alerts that clinical engineering teams cannot realistically patch.

The Friction of Fifteen-Year Lifecycles in an Era of Instant Exploits

A medical device SBOM is now a regulatory mandate under FDA Section 524B, yet manufacturers face a stark gap between paper compliance and clinical safety.

Consider a connected infusion pump or a clinical ventilator cleared for market use today. That physical chassis is designed to remain in active clinical service for twelve to fifteen years. However, the software running inside it begins to decay the moment it leaves the factory. Open-source libraries go unsupported, new vulnerability classes emerge, and frontier AI tools now allow adversaries to find and exploit legacy code flaws at unprecedented speed. This reality creates an operational crisis for medical device manufacturers and hospital security teams alike.

In June 2025, the FDA finalized its updated premarket cybersecurity guidance, effectively weaponizing its Refuse to Accept (RTA) authority against manufacturers who submit incomplete software inventories. The regulatory shift from recommendations to mandates—echoed globally by the EU Medical Device Regulation (EU MDR)—has forced the industry to adopt the SBOM as a baseline requirement. Yet, the commercial promise of these "digital ingredient labels" often collides with the messy reality of clinical operations.

The Tooling Pipeline vs. The Engineering Sandbox

To understand why SBOM implementation stalls, one must look at how these inventories are generated and analyzed. In theory, an SBOM is a clean, automated export in a standardized format like SPDX or CycloneDX. This file is fed into a vulnerability scanner, which cross-references the components against the NIST National Vulnerability Database (NVD) to flag active Common Vulnerabilities and Exposures (CVEs).

An SBOM is like a restaurant menu listing raw ingredients; it tells you that peanuts are in the kitchen, but it cannot tell you if the chef used a clean knife or if the allergen actually reached the plate. In the same way, a scanner can flag a vulnerability in a TCP/IP stack without knowing if that specific protocol is disabled in the device configuration.

Newer market entrants, such as the partnership between Enlil and Interlynk, target Software-as-a-Medical Device (SaMD) and AI-driven clinical systems by offering dynamic tracking. Meanwhile, utility tools like ICS SBOMGuard allow teams to import SPDX files and track CVE justifications over time. But these tools operate on two fundamentally different philosophies of risk management.

The Illusion of the Automated Green Checkmark

The most common failure point in medical device security is the belief that automated scanning equals risk reduction. When a scanner runs against a static medical device firmware image, it typically flags dozens of high-severity CVEs. The vast majority of these are false positives because the vulnerable code paths are unreachable during normal device operation.

"A vulnerability is only a threat if there is an active path to reach it; without that path, a patch is just unnecessary surgery on a healthy patient."

Anatomy of a Postmarket Vulnerability Storm

To see how this tension plays out in a clinical setting, let us trace what happens when a new vulnerability is disclosed in a common embedded component, such as an older version of the OpenSSL library used for secure telemetry in a patient monitor.

  1. The Automated Ingestion: The manufacturer's security platform imports the device's master SPDX file and flags a critical vulnerability in the cryptographic module. The system automatically generates a compliance alert, starting a regulatory clock under postmarket monitoring rules.
  2. The Reachability Analysis: Engineering must determine if the vulnerable OpenSSL function is actually called by the monitor's operating system. This requires manual code review, binary analysis, and runtime testing in a hardware-in-the-loop simulator to see if an attacker could trigger the flaw via the hospital network.
  3. The VEX Documentation: If the vulnerability is found to be unreachable, the manufacturer does not write a patch. Instead, they must author a Vulnerability Exploitability eXchange (VEX) document, proving to regulators and hospital clients that the device remains safe without modification, thereby avoiding a costly firmware revalidation cycle.

Continuous Automation vs. Risk-Based Engineering Triage

When designing an SBOM compliance program, manufacturers must choose between two distinct operational strategies. Neither is a universal cure; each represents a calculated trade-off in engineering hours, software quality, and regulatory risk.

Operational Metric Continuous Automation (Dynamic SBOM) Risk-Based Triage (Point-in-Time)
Primary Focus Real-time compliance and continuous tool integration Clinical exploitability and deep architectural analysis
Engineering Overhead High initial setup; constant alert monitoring High episodic effort during scheduled audits
Regulatory Alignment Excellent for SaMD and rapid cloud deployments Suited for static, long-lifecycle hardware firmware
False Positive Rate High; requires continuous manual suppression Low; filtered through threat modeling before logging

The Continuous Automation approach relies on software pipelines to ingest, scan, and report vulnerabilities constantly. This method is highly favored by software developers working on active, cloud-hosted SaMD platforms where code changes weekly. The friction here is noise. The constant influx of NVD updates creates alert fatigue, often leading security teams to ignore critical warnings buried under a mountain of irrelevant notifications.

Conversely, the Risk-Based Triage model treats SBOM management as a deliberate, engineering-led audit. Instead of scanning every day, the team conducts deep-dive threat modeling at set intervals or major release milestones. They prioritize vulnerabilities that have known public exploits and direct paths to clinical impact. The trade-off is speed. If a zero-day exploit emerges between audit cycles, the manufacturer may remain unaware of their exposure window until the next scheduled assessment.

The deciding variable is the rate of change of the device's software stack. If you are building cloud-connected AI diagnostic software that updates every month, you must build a continuous, automated SBOM pipeline to survive. If you are maintaining a fleet of legacy, offline anesthesia machines with static firmware, attempting continuous automated scanning is an expensive exercise in chasing ghosts; a rigorous, point-in-time risk assessment combined with compensating network controls is the only pragmatic path forward.

Where Paper Compliance Collides with Clinical Reality

  • The SBOM is a security solution: An SBOM is merely an inventory, not a defensive control. Generating a list of ingredients does not make a device secure; it only makes its vulnerabilities visible.
  • Every flagged CVE requires an immediate patch: In clinical environments, pushing an unvalidated firmware patch can cause device instability, which poses a far greater risk to patient safety than an unexploited network vulnerability.
  • Automated tools eliminate the need for security expertise: Scanners lack clinical context. They cannot determine if a device is protected by microsegmentation or if a vulnerable port is physically blocked on the hospital floor; human engineering judgment remains the final line of defense.

Frequently Asked Questions

What happens to our FDA compliance status if a critical vulnerability is discovered in a third-party library we cannot patch?

Under FDA Section 524B, you are not penalized for utilizing unpatchable third-party libraries, provided you document the risk. You must update your postmarket monitoring records, perform a clinical risk assessment, and issue a VEX file demonstrating that the vulnerability is either unreachable or mitigated by compensating controls, such as disabling unused services or requiring network-level authentication.

How do we handle SBOM versioning when our device uses a mix of static firmware and frequently updated cloud-based AI models?

This hybrid architecture requires a split SBOM strategy. The static, hardware-bound firmware should have a stable, version-controlled SPDX or CycloneDX file generated at release. The cloud-based AI components require a dynamic pipeline that updates automatically with each model deployment, typically running version intervals of 2 to 4 weeks, to maintain compliance with EU MDR and FDA premarket requirements.

In the end, the value of a medical device SBOM is not found in the software that generates it, but in the engineering culture that interprets it. True security is achieved not by checking a regulatory box, but by systematically understanding how your code behaves when the clinical stakes are highest.

Related from this blog

Sources

Next Post Previous Post
No Comment
Add Comment
comment url